RXi Q2 Losses Hold Steady | GenomeWeb

RXi Q2 Losses Hold Steady


NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week reported its financial results for the second quarter, posting an unchanged net loss as expenses largely held steady from last year.

The company's loss of the three-month period ended June 30 was $2 million, the same as the year before. Research and development spending held steady at $1.2 million, while general and administrative costs edged up $100,000 to $1 million.

At the end of the quarter, RXi had cash and cash equivalents of roughly $11.9 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Genome editing is also bringing up questions when applied to farm animals, the New York Times reports.

Through a transcriptome study, researchers home in on the activity of inflammation-linked genes in chronically lonely people.

Determining who is and is not an author and where a researcher should fall on a list of authors can be a tricky task, Nature News writes.

In PNAS this week: variant protective against Alzheimer's disease, effect of whole-genome duplication on methylation in rice, and more.

Sponsored by
HTG Molecular

This webinar will discuss potential clinical applications for miRNA signatures and a novel, extraction-free miRNA profiling technology for advancing biomarker discovery.